Welcome to our dedicated page for Cellectar Biosciences NEW news (Ticker: CLRB), a resource for investors and traders seeking the latest updates and insights on Cellectar Biosciences NEW stock.
Cellectar Biosciences Inc. (symbol: CLRB) is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative drugs aimed at treating cancer. The company's core focus is leveraging its proprietary Phospholipid Drug Conjugate (PDC) delivery platform, which is designed to target cancer cells specifically, thereby enhancing efficacy and reducing off-target effects.
Cellectar's PDC platform is founded on proprietary phospholipid ether analogs, small molecules known for their selective uptake and retention in various cancers. This technology underpins the company's product pipeline, which includes both therapeutic and diagnostic agents for oncology. The lead therapeutic candidate, CLR 131, utilizes the cytotoxic radioisotope iodine-131 as its payload. CLR 131 has received orphan drug designation from the US FDA and is currently being evaluated in a Phase 1 clinical study for relapsed or refractory multiple myeloma and a Phase 2 clinical study for a range of B-cell malignancies.
In addition to CLR 131, Cellectar is working on developing proprietary PDCs for targeted chemotherapeutic delivery, with several candidates in preclinical stages. The company actively collaborates with research and development partners to expand its PDC platform's applications.
Financially, Cellectar maintains a robust pipeline and continues to secure funding for its clinical and preclinical programs. The company’s innovative approach and partnerships highlight its significant role in the biopharmaceutical landscape.
For more detailed and latest updates, please visit Cellectar’s official website or follow their social media channels.
News
Rhea-AI Summary
Cellectar Biosciences, Inc. (CLRB) announced positive financial results for 2023 and provided a corporate update, highlighting significant progress in its pivotal study of iopofosine I 131 in Waldenstrom’s macroglobulinemia. The company reported a major response rate of 61% in relapsed/refractory patients, with durable responses and high rates of disease control. Additionally, Cellectar achieved a complete remission rate of 64% in head and neck cancer patients and demonstrated complete clonal clearance in a patient with Bing-Neel Syndrome. The company also initiated a Phase 1b study in pediatric high-grade gliomas and presented promising preclinical data for CLR 121255 in pancreatic cancer models. Cellectar expanded its IP protection and successfully exercised Tranche A warrants, raising approximately $44.1 million. Financially, the company had $9.6 million in cash and cash equivalents as of December 31, 2023, with a net loss of ($38.0) million for the year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.45%
Tags
-
Rhea-AI Summary
Cellectar Biosciences, Inc. (CLRB) will release its financial results for the year ended December 31, 2023, on March 27, 2024. The company, specializing in cancer treatment drugs, will host a conference call at 8:30 am Eastern Time to discuss the results with investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
-
Rhea-AI Summary
Cellectar Biosciences, Inc. (CLRB) announces Jim Caruso, the President and CEO, will present at the 36th Annual Roth Conference. The presentation will focus on the company's overview and future prospects in cancer drug development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.52%
Tags
Rhea-AI Summary
Cellectar Biosciences, Inc. (CLRB) announces positive results from a Phase 1 clinical trial showcasing a 64% complete remission rate and a 73% overall response rate in highly refractory patients with head and neck squamous cell carcinoma. The study also highlights a 67% overall survival and a 42% progression-free survival at one year. The combination of iopofosine I 131 with external beam radiation therapy was well-tolerated, showing promising therapeutic effects without significant toxicity increase.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.95%
Tags
-
News
Rhea-AI Summary
Cellectar Biosciences, Inc. (NASDAQ: CLRB) announced that James Caruso, president and CEO, will present an overview of the company at the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The presentation will be held virtually on February 14, 2024, at 2:00 – 2:30 pm Eastern Time. A webcast will be available, and a replay can be accessed on the company's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
-
Rhea-AI Summary
Cellectar Biosciences, Inc. (NASDAQ: CLRB) has announced the enrollment of the first patient in its Phase 1b clinical trial for iopofosine I 131, a novel phospholipid radiotherapeutic conjugate, in pediatric patients with relapsed or refractory malignant high-grade gliomas (pHGG). The study is supported by a $2 million Fast Track SBIR grant from the National Institute of Health’s National Cancer Institute (NCI). The company aims to identify the optimal iopofosine I 131 Phase 2 recommended dose and schedule in pHGG patients and evaluate safety and tolerability. The treatment has shown promising results in a relapsed, refractory Bing-Neel Syndrome patient and demonstrated clinical activity across the blood-brain barrier in other hematologic malignancies. Cellectar is hopeful that its novel mechanism of action will provide a meaningful treatment option for pediatric patients with high-grade gliomas.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.7%
Tags
Rhea-AI Summary
Cellectar Biosciences, Inc. (NASDAQ: CLRB) announced the full exercise of Tranche A warrants from a previous private placement, resulting in gross proceeds of approximately $44.1 million. Additionally, the company issued Tranche B warrants for potential aggregate proceeds of approximately $34.3 million. The Tranche B warrants contain a trigger for investors to exercise following the Company's public announcement of its receipt of written approval from the U.S. FDA of its New Drug Application (NDA) for iopofosine I 131, or September 8, 2028. The president and CEO, James Caruso, expressed confidence in the company's lead asset, iopofosine I 131, and highlighted the strengthened balance sheet and investor support for achieving near-term milestones, including NDA submission and potential accelerated FDA approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.85%
Tags
-
Rhea-AI Summary
Cellectar Biosciences, Inc. announces successful pathological response with complete clonal clearance in a patient with relapsed/refractory Waldenstrom’s macroglobulinemia (WM) and CNS involvement using iopofosine I 131. This validates the potential of the drug to treat CNS malignancies, including CNS lymphoma and pediatric high-grade gliomas. The company has also initiated a Phase 1b study in pediatric high-grade gliomas with the support of a $2 million grant from the National Cancer Institute.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.6%
Tags
-
Rhea-AI Summary
Cellectar Biosciences, Inc. announced promising preclinical data for its proprietary novel alpha-emitting phospholipid radiotherapeutic conjugate, CLR 121225, in pancreatic cancer models. The compound demonstrated potent anti-tumor activity in refractory pancreatic cancer mouse xenograft models, with a single administration resulting in tumor volume reduction in a dose-dependent manner. The data also showed excellent biodistribution and good tolerability, supporting the continued development of CLR 121225 for a Phase 1 first-in-human study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.41%
Tags
Rhea-AI Summary
Cellectar Biosciences, Inc. (NASDAQ: CLRB) to Host Conference Call with Dr. Levy to Discuss Positive Results of Iopofosine I 131 in Waldenstrom's Macroglobulinemia Treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.03%
Tags
FAQ
What is the current stock price of Cellectar Biosciences NEW (CLRB)?
The current stock price of Cellectar Biosciences NEW (CLRB) is $0.3454 as of January 3, 2025.
What is the market cap of Cellectar Biosciences NEW (CLRB)?
The market cap of Cellectar Biosciences NEW (CLRB) is approximately 13.0M.
What is Cellectar Biosciences' primary focus?
Cellectar Biosciences focuses on developing drugs for cancer treatment using their proprietary Phospholipid Drug Conjugate (PDC) delivery platform.
What is the lead therapeutic candidate of Cellectar Biosciences?
The lead therapeutic candidate is CLR 131, a PDC that uses iodine-131 to target and kill cancer cells.
What are the current clinical trials for CLR 131?
CLR 131 is undergoing a Phase 1 clinical study for relapsed or refractory multiple myeloma and a Phase 2 study for various B-cell malignancies.
Has CLR 131 received any designations from the FDA?
Yes, CLR 131 has been designated as an orphan drug by the US FDA.
What is the proprietary technology behind Cellectar's PDC platform?
The PDC platform is based on proprietary phospholipid ether analogs that selectively uptake and retain in cancer cells.
Is Cellectar Biosciences involved in any partnerships?
Yes, the company collaborates with research and development partners to expand the applications of its PDC platform.
What other products are under development at Cellectar?
Cellectar is developing additional PDCs for targeted chemotherapeutic delivery, with several in preclinical stages.
Where can I find more information about Cellectar Biosciences?
For more information, visit the official Cellectar Biosciences website or follow their social media channels.
How does Cellectar's PDC platform improve cancer treatment?
The PDC platform targets cancer cells specifically, enhancing treatment efficacy and reducing off-target effects.
What makes Cellectar Biosciences significant in the biopharmaceutical field?
Cellectar's innovative targeted delivery platform and its robust clinical pipeline highlight its significant role in advancing cancer treatment.
Cellectar Biosciences INC NEW
Nasdaq:CLRB
CLRB Rankings
CLRB Stock Data
12.99M
37.66M
2.84%
34.55%
4.52%
Biotechnology
Pharmaceutical Preparations
United States of America
FLORHAM PARK